As the effects of statin on circulation in small vessels has not been completely elucidated, a study published in the Cardiovascular Diabetology journal assessed the effect of rosuvastatin on biomarkers, including paraoxonase-1 (PON-1) and asymmetric dimethylarginine (ADMA), and on microvascular reactivity. The results showed that rosuvastatin therapy for 12 weeks improved microvascular reactivity with concomitant beneficial changes in the postprandial levels of PON-1 and ADMA. Low-density lipoprotein-cholesterol decreased from 147.2 ± 26.5 to 68.3 ± 24.5 mg/dL and high-density lipoprotein-cholesterol increased from 42.4 ± 5.2 to 44.7 ± 6.2 mg/dL on treatment with rosuvastatin. These results indicate that rosuvastatin helps in improving the postprandial cardiometabolic milieu in patients with type 2 diabetes.